Insmed, a biopharmaceutical specialist in rare diseases, is stealing the spotlight in 2025 with a stunning 62% gain, ...

We expect Amgen AMGN to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the last reported quarter, the company beat earnings expectations by 17.8%. The ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

Aquent is a multinational staffing and recruiting agency that places design and marketing professionals in permanent and ...

Valley Wealth Managers Inc. just upped their Amgen game by 8.1% this quarter, now holding a cool $27.15 million worth of ...

Kissei Pharmaceutical is paying Viridian Therapeutics $70 million upfront for Japanese rights to a pair of thyroid eye ...

On July 24, Emily Roland, Manulife John Hancock Investments co-chief investment strategist, appeared on CNBC’s ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...